Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 136

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 136
---
 not limited to:

| ● | our ability to begin earning positive revenues; |

| ● | the costs of expanding our operations, including our business development and marketing efforts; |

| ● | our rate of progress, once our products are approved, in selling access to products and marketing activities 
 associated therewith;                                                                                        |

| ● | our rate of progress in, and cost of research and development activities associated with product candidates; |

| ● | the effect of competing technological and market developments; |

| ● | our efforts to enhance our operational systems and hire additional personnel to satisfy our obligations 
 as a public company;                                                                                    |

| ● | the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable 
 foreign regulatory authorities;                                                                             |

| 56 |

| ● | the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents and 
 other intellectual property and proprietary rights; and                                                |

| ● | the costs associated with any technologies that we may in-license or acquire. |

The various ways
we could raise additional capital carry potential risks. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other
preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may
involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt,
making capital expenditures or declaring dividends. Such restrictions could adversely impact our ability to conduct our operations and
execute our business plan.

Our ability to
raise additional capital may also be adversely impacted by conditions in the financial markets at the time we are seeking capital. If
we are unable to obtain adequate financing if required, when needed or on terms acceptable to us, our ability to continue to pursue our
business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited,
and could have a material adverse effect on our business, financial condition, results of operations and prospects.

If we fail to maintain
an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial
statements or comply with applicable regulations could be impaired.

As a publicly
traded company following the consummation of the Business Combinations, we will be subject to the reporting requirements of the Exchange
Act, the Sarbanes-Oxley Act and the rules and regulations of the